论文部分内容阅读
我们用RIA法测定79例血清β_2-MG 浓度,计正常人13例、胃癌患者38例,结/直肠癌患者9例、非胃肠道癌患者9例、良性胃病患者10例。对其中40例胃肠道癌患者术后进行2～5次随访检测,并结合胃镜、X 线及B 超等检查,观察手术前后患者血清β_2-MG 的变化及与近期疗效的关系。材料与方法血清来源:正常人系无胃肠道疾患、无肿瘤病史者;癌患者系我院内、外科住院病人,均经手术及病理检查确诊,随访时间多在术后1～2年内,少数在2年以上;良性胃病患者均经内窥镜或其它方法确诊,计慢性胃炎3例、
We used RIA method to determine the concentration of serum β_2-MG in 79 patients, including 13 normal subjects, 38 gastric cancer patients, 9 colorectal cancer patients, 9 non-gastrointestinal cancer patients, and 10 benign gastropathy patients. 40 cases of gastrointestinal cancer patients were followed up for 2 to 5 follow-up tests, combined with gastroscopy, X-ray and B-ultrasound and other tests to observe the changes of serum β2-MG in patients before and after surgery and its relationship with the short-term efficacy. Materials and Methods Serum sources: normal humans have no history of gastrointestinal disorders and no history of cancer; patients with cancer are hospitalized and inpatients in our hospital. All patients were diagnosed by surgery and pathological examination. The follow-up time was mostly within 1 to 2 years after surgery. In 2 years or more; Benign gastropathy patients were diagnosed by endoscopy or other methods, including chronic gastritis in 3 cases.